Jazz Pharmaceuticals (JAZZ) Interest Expenses (2010 - 2026)

Jazz Pharmaceuticals' Interest Expenses history runs 17 years deep, the most recent figure standing at $578.5 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 8.27% year-over-year to $578.5 million in Q1 2026; TTM through Mar 2026 was $578.5 million, a 8.27% decrease from a year earlier, with the FY2025 full-year figure at $647.3 million, up 27.12% from the prior year.
• Interest Expenses advanced to $578.5 million in Q1 2026 per JAZZ's latest filing, from $31.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $647.1 million in Q3 2024 and bottomed at $8.6 million in Q2 2024.
• The 5-year median for Interest Expenses is $602.4 million (2023), against an average of $470.0 million.
• Across the five-year window, Interest Expenses slumped 98.61% in 2024 and soared 7398.91% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $25.2 million in 2022, then surged by 1155.21% to $316.3 million in 2023, then retreated by 1.2% to $312.5 million in 2024, then sank by 89.98% to $31.3 million in 2025, then surged by 1748.24% to $578.5 million in 2026.
• Per Business Quant, the three latest JAZZ Interest Expenses figures stand at $578.5 million (Q1 2026), $31.3 million (Q4 2025), and $638.4 million (Q3 2025).